Objective To investigate the relationship between serum microRNAs(miRNAs,miR)-216b and miR-132 expressions and clinical prognosis in patients with gastric cancer.Methods From January 2018 to February 2020,87 gastric cancer patients who visited Jiamusi Central Hospital were selected as the gastric cancer group,while 87 healthy individuals who underwent physical examinations in the hospital were collected as the control group.Quantitative real-time PCR(qRT-PCR)was applied to detect the expression levels of miR-216b and miR-132 in serum.The relationship between the expression levels ofmiR-216b and miR-132 in the serum of gastric cancer patients and their clinical pathological characteristics was analyzed.According to the survival or death status of gastric cancer patients during the follow-up period,these patients were divided into a good prognosis group(survival,n=51)and a poor prognosis group(death,n=36).The predictive value of serum miR-216b and miR-132 expression levels on the prognosis of gastric cancer patients was analyzed using the receiver operating characteristic(ROC)curve.COX regression was applied to analyze factors affecting the prognosis of gastric cancer patients.Results Compared with the control group,the expression levels of miR-216b(0.69±0.20vs1.02±0.24)and miR-132(0.73±0.19 vs 1.01±0.22)in serum of gastric cancer group were decreased,and the differences were significant(t=9.853,8.984,all P＜0.001).The expression levels of miR-216b and miR-132 in serum of gastric cancer patients with low differentiation,TNM stages Ⅲ±Ⅳ,lymph node metastasis,and distant metastasis were significantly lower than those of gastric cancer patients with medium and high differentiation,TNM stages Ⅰ±Ⅱ,no lymph node metastasis and no distant metastasis,and the differences were statistically significant(t=6.266,3.412,2.890,2.723;4.999,3.734,4.180,5.502,all P＜0.05).Compared with the good prognosis group,the expression levels of miR-216b(0.56±0.16 vs 0.78±0.23)and miR-132(0.60±0.11 vs 0.82±0.25)in serum of gastric cancer patients in the poor prognosis group were decreased,and the differences were statistically significant(t=4.952,4.946,all P＜0.001).The areas under the cure(AUC)of serum miR-216b,miR-132 and their combination predicted the prognosis of gastric cancer patients was 0.797(95％CI:0.706～0.889),0.832(95％CI:0.745～0.918)and 0.900(95％CI:0.836～0.964),respectively.The sensitivity and specificity were 83.3％,68.6％;97.2％,62.7％and 79.4％,72.5％,respectively.When the cut-off values of serum miR-216b and miR-132 for predicting poor prognosis of gastric cancer patients were 0.66 and 0.76,respectively,the sensitivity of the prediction were relatively high.COX regression analysis showed that low expression of miR-216b and miR-132,poorly differentiated degree,TNM stage Ⅲ+Ⅳ,lymph node metastasis,and distant metastasis were risk factors for poor prognosis in gastric cancer patients(all P＜0.05).Conclusion MiR-216b and miR-132 were low expressed in the serum of gastric cancer patients,and they could serve as effective biomarkers for predicting the prognosis of gastric cancer patients.